Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
38214
CAS Number:
129101-54-8
L-tartrato de rivastigmina
Purity:
≥ 98% (ensayo por titulación, HPLC)
Synonym(s):
N -Etil- N -metilcarbamato de 3-[( S -1-(dimetilamino)etil]fenilo L-tartrato, Éster L-tartrato de 3-[( S -1-(dimetilamino)etil]fenilo del ácido N -etil- N -metilcarbámico
Hazmat
Documents
$204.31 /1G
Tamaño
Request Bulk Quote
Información del producto
Número CAS
129101-54-8
Fórmula molecular
C14H22N2O2 · C4H6O6
Peso molecular
0
Número MDL
MFCD03700731
Punto de fusión
124 - 128 °C
Rotación óptica
[a] D 20 = 4 - 7 ° (C = 5 en metanol)
Condiciones
Conservar entre 2 y 8 °C.
Información general
Número CAS
129101-54-8
Fórmula molecular
C14H22N2O2 · C4H6O6
Peso molecular
0
Número MDL
MFCD03700731
Punto de fusión
124 - 128 °C
Rotación óptica
[a] D 20 = 4 - 7 ° (C = 5 en metanol)
Condiciones
Conservar entre 2 y 8 °C.
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Rivastigmine L-tartrate is widely utilized in research focused on:

  • Alzheimer's Disease Treatment: This compound is primarily used as a medication to manage symptoms of Alzheimer's disease, helping to improve cognitive function and slow disease progression.
  • Parkinson's Disease Management: It is also effective in treating dementia associated with Parkinson's disease, providing relief from cognitive decline in patients.
  • Neuropharmacological Research: Researchers use Rivastigmine L-tartrate to study its effects on neurotransmitter systems, particularly in understanding cholinergic function and its role in memory and learning.
  • Formulation Development: The compound is utilized in the development of various pharmaceutical formulations, including transdermal patches, which enhance patient compliance and provide controlled drug delivery.
  • Clinical Trials: Rivastigmine L-tartrate is frequently involved in clinical trials aimed at evaluating new treatment protocols for neurodegenerative diseases, contributing to advancements in therapeutic strategies.

Citas